SynthesisInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021
Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis.
Synthesis in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Systemic inflammation index, disease severity, and mortality in patients with COVID-19: a systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression.Clinical and experimental medicine · 2022Pooled it
- Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.Advances in medical sciences · 2021Pooled it
- Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.Frontiers in immunologyPooled it
- Surface cues shape procoagulant properties of amyloidogenic microclots.Cell death & disease · 2026Review
- The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 (COVID-19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill.Journal of clinical laboratory analysis · 2026Article
- Intranasal SARS-CoV-2 infection changes the transcriptome of the mouse trigeminal ganglion and brainstem: potential mechanisms underlying headache and trigeminal pain presentation in COVID-19.Journal of neuroinflammation · 2026Article
- Viral Prognosis Using Proteomics.Advances in experimental medicine and biology · 2026Review
- Serum amyloid A: multifaceted roles in inflammation and cellular interactions.Immunologic research · 2025Review
- Severe COVID-19 induces prolonged elevation of the acute-phase protein pentraxin 3.Frontiers in immunology · 2025Article
- Proteomic analysis of lung responses to SARS-CoV-2 infection in aged non-human primates: clinical and research relevance.GeroScience · 2024Article
- Key charged residues influence the amyloidogenic propensity of the helix-1 region of serum amyloid A.Biochimica et biophysica acta. General subjects · 2024Article
- Complex changes in serum protein levels in COVID-19 convalescents.Scientific reports · 2024Article
- Exploring the Potential Long-term Impact of SARS-CoV-2 on Protein Misfolding and Amyloid-related Conditions.Protein and peptide letters · 2024Review
- New Regulatory roles for Human Serum Amyloid A.International journal of research in oncology · 2024Article
- IL-6 and SAA-Strong Predictors for the Outcome in COVID-19 CKD Patients.International journal of molecular sciences · 2023Article
- Post COVID-19 complications and follow up biomarkers.Nanoscale advances · 2023Review
- Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report.Yonsei medical journal · 2023Article
- COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?Vaccines · 2023Review
- An Updated Systematic Review and Meta-Analysis of the Association between the De Ritis Ratio and Disease Severity and Mortality in Patients with COVID-19.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAn excessive inflammatory response in patients with coronavirus disease 2019 (COVID-19) is associated with high disease severity and mortality. Specific acute phase reactants might be useful for risk stratification. A systematic review and meta-analysis was conducted of studies on serum amyloid A (SAA) in patients with COVID-19.
methodsThe PubMed, Web of Science, and Scopus databases were searched, covering the period January 2020 to December 2020, for studies reporting SAA concentrations, COVID-19 severity, and survival status.
resultsNineteen studies involving 5617 COVID-19 patients were included in the meta-analysis. Pooled results showed that SAA concentrations were significantly higher in patients with severe disease and non-survivors (standard mean difference (SMD) 1.20, 95% confidence interval 0.91-1.49, P < 0.001). Extreme between-study heterogeneity was observed (I
conclusionsSAA concentrations were significantly and positively associated with higher COVID-19 severity and mortality. This acute phase reactant might assist with risk stratification and monitoring in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.